MEDIAN Technologies strenghtens IP portfolio with US patent
Notice of Allowance of the United States Patent and Trademark Office (USPTO) for patent application covering a set of image processing algorithms developed by MEDIAN Technologies.
MEDIAN Technologies (ALMDT), a leading medical imaging solutions and service provider for image interpretation and management in oncology, announces that it has strengthened its IP portfolio following the United States Patent and Trademark Office’s (USPTO) Notice of Allowance related to the patent US 9092691 B1.
The patent application covers a set of computing systems and methods to automatically extract biomarkers from medical images. Those imaging biomarkers will allow physicians to identify and classify pathologies for most cancers; they also will allow physicians to determine which patients are more likely to respond to a specific therapy and to evaluate assess their response to therapy.
Imaging biomarkers have a tremendous potential in the evaluation of response to therapy of cancer patients. By providing highly reliable indexes of therapy efficacy, imaging biomarkers are key to evaluate cytotoxic or non-cytotoxic drugs during clinical trials, and to diagnose and follow patients in clinical routine.
“This patent further strengthens our intellectual property around our Lesion Management Solution (LMS) technology. It covers methods to compute imaging biomarkers from standard imaging techniques, such as CT scanner and MRI. Those imaging techniques are widely available in hospital imaging departments, used in clinical routine and completely non-invasive”, said Fredrik Brag, CEO of MEDIAN Technologies. “Moreover, we are proud to continue our Research and Development activities within the field of advanced imaging biomarkers, as they are essential for the development of personalized medicine in oncology and in other therapeutic areas”.